Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Barchart · 2d ago

Topline six-month efficacy data expected by end of 2027

Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.